USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
DiaCarta
Address:
3535 Breakwater Avenue
Hayward, CA
Phone:
(510) 818-2656
URL:
N/A
EIN:
61821062
DUNS:
803607154
Number of Employees:
6
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $594,739.00 1
STTR Phase I $99,000.00 1
STTR Phase II $749,291.00 1

Award List:

Novel Methods for Rapid Detection of Infection Agents and the Severity of Cellular Damage

Award Year / Program / Phase:
2008 / STTR / Phase I
Award Amount:
$99,000.00
Agency / Branch:
DOD / DARPA
Principal Investigator:
Aiguo Zhang, Principal Investigator
Research Institution:
UNIV. OF ROCHESTER
RI Contact:
Donna Beyea
Abstract:
The development of early detection methods to aid in the identification of virulent infectious pathogens is of strategic importance so that exposed warfighters and other individuals can be treated early or appropriately quarantined. We are currently developing a nucleic acid-based assay that can… More

Novel Methods for Rapid Detection of Infection Agents and the Severity of Cellular Damage

Award Year / Program / Phase:
2010 / STTR / Phase II
Award Amount:
$749,291.00
Agency / Branch:
DOD / DARPA
Principal Investigator:
Lulu Zhang, Principal Investigator – (517) 378-3758
Research Institution:
University of Rochester
RI Contact:
Donna Beyea
Abstract:
Early detection of virulent infectious pathogens is critical to blocking the devastating epidemic spread of the pathogen and the potential harm this could have on our armed forces and general populations. In Phase I, we have utilized the state-of-the-art QuantiGene 2.0 technology to establish an… More

FGF-P to treat post-irradiation GI syndrome

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$594,739.00
Agency:
HHS
Principal Investigator:
Aiguo Zhang – 510-314-8858
Abstract:
DESCRIPTION (provided by applicant): For victims of gastrointestinal (GI) radiation exposure and concomitant GI syndrome, DiaCarta's fibroblast growth factor-peptide (FGF-P) is a product that will not only reduce depopulation and improve reepithelialization of the small bowel but also support… More